Metenolone


Full Prescribing Info
Dosage/Direction for Use

Oral
Aplastic anaemia
Adult: As acetate: 100-150 mg/day.

Intramuscular

Postmenopausal osteoporosis
Adult: As enantate: 100 mg every 2 wk, then reduce to once every 3-4 wk after an initial response.

Intramuscular

Progressive breast cancer
Adult: As enantate: 100 mg every 1-2 wk or 200 mg every 2-3 wk.
Administration
May be taken with or without food.
Contraindications
Pregnancy. In men, prostate or breast carcinoma, other hormone-dependent carcinoma.
Special Precautions
Lactation; CV disorders, renal or hepatic impairment, epilepsy, migraine, DM, conditions aggravated by fluid retention. Children. Regularly examine prostate in men.
Adverse Reactions
Fluid and electrolyte retention, psychiatric effects, hypercalcaemia, impaired glucose tolerance, increased bone growth and skeletal weight. Men: Impotence, priapism, azoospermia, prostatic hypertrophy; gynaecomastia, hirsutism, male pattern baldness, acne, seborrhoea, oedema, cholestatic jaundice. Women: Virilisation, amenorrhoea, menstrual irregularities, suppressed lactation, increased libido. Children: Premature closure of epiphyses, stops linear growth, virilisation symptoms.
Drug Interactions
May enhance effects of antidiabetics, ciclosporin, levothyroxine, warfarin. Resistance to the effects of neuromuscular blockers may occur.
Lab Interference
May interfere with glucose tolerance and thyroid function tests.
Action
Metenolone is an anabolic steroid, which in high doses stimulates bone marrow functions, particularly erythropoiesis.
Storage
Oral: Store below 30°C.
ATC Classification
A14AA04 - metenolone ; Belongs to the class of androstan derivative anabolic steroids used as systemic anabolic agents.
Disclaimer: This information is independently developed by CIMS based on metenolone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in